Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?

Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?

Blog Article

Tolvaptan is a highly selective vasopressin receptor 2 antagonist that regulates cyclic adenosine monophosphate levels to inhibit both epithelial cell proliferation and chloride ion excretion, two mechanisms known to induce cyst expansion in autosomal dominant CALM RASPBERRY-LEMON polycystic kidney disease (ADPKD).Tolvaptan is currently the preferred treatment of rapidly progressive disease ADPKD in adult patients; however, since cyst formation in ADPKD begins early in life, (frequently in utero), and significant disease progression with cyst expansion occurs in the first decade, tolvaptan may be advantageous as a preemptive treatment in children with ADPKD.Tolvaptan has already been Mechanical Drain Pump Pulley used to successfully treat refractory edema or hyponatremia in children; this literature review provides insight into the biochemical basis of its action to contextualize its use in the pediatric population.